Drug Evaluation in the Plasmodium falciparum-Aotus Model.
Abstract
The purpose of these studies was to evaluate experimental antimalarial drugs in a non-human primate model, viz. blood-induced infections of Plasmodium falciparum or P. vivax in the owl monkey, Aotus trivirgatus. Two strains of falciparum malaria, Uganda Palo Alto (sensitive to chloroquine and quinine, resistant to pyrimethamine) and Vietnam Smith (resistant of chloroquine, quinine and pyrimethamine), were used in these experiments. The strain of P. vivax was the New Guinea Chesson strain (sensitive to chloroquine, quinine and pyrimethamine). Results of the assessment of WR 245082, and acridineimine, indicated that its curative activity against the chloroquine-sensitive and the chloroquine-resistant strain was essentially identical. Three 8-aminoquinolines were evaluated for their activity against blood-induced infections of P. vivax. WR 249420, WR 249252 and WR 249700 were curative. An acridinol, WR 250547, cured blood-induced infections of P. vivax. WR 247705, a quinoline, was assessed for its activity against infections of the Uganda Palo Alto strain of P. falciparum. WR 251853, 2-fluoro-L-Histidine suppressed and parasitemia of the Uganda Palo Alto strain. WR 079520, desferrioxamine, an iron-specific chelating agent, was administered to Aotus infected with the Uganda Palo Alto strain of P. falciparum. The infection was not cured. The in vitro activity of deferrioxamine was not substantiated in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 30, 1985
- Accession Number
- ADA187403
Entities
People
- Richard N. Rossan